Lipoprotein(a) as a Predictor of Major Adverse Cardiovascular Events in Patients with Acute Coronary Syndrome
Journal of Clinical Medicine · 05.08.2026 · 15 (15) · 6086
DOI: 10.3390/jcm15156086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 05.08.2026. Verfasst von Xinhang Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Fourth Afffliated Hospital of Harbin Medical University, Harbin 150001, China. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Harbin Medical University.
Abstract (Originalsprache)
Background
Despite recent advances in reperfusion strategies, acute coronary syndrome (ACS) patients remain at high risk for recurrent major adverse cardiovascular events (MACE). This study aims to investigate the association between lipoprotein(a) (Lp(a)) and MACE in ACS patients, and to systematically evaluate its predictive performance, incremental prognostic value and clinical utility.
Methods
This retrospective cohort study included 300 ACS patients with a 1-year follow-up. Serum Lp(a) levels were measured by immunoturbidimetry using fasting venous blood samples collected on the day of admission. Kaplan–Meier and Cox regression analyses were used to assess the association between Lp(a) and MACE. Subgroup and interaction analyses were performed to test the robustness of the findings. Incremental predictive value and net clinical benefit were evaluated using receiver operating characteristic (ROC) curves, the DeLong test, decision curve analysis (DCA) and the integrated discrimination improvement (IDI) index.
Results
Baseline Lp(a) levels were significantly higher in the event group (p = 0.006). A significantly lower cumulative survival probability was found in patients with elevated Lp(a) (log-rank p = 0.0014). As a standalone predictor of MACE, Lp(a) yielded an AUC of 0.606 (p = 0.006). The AUC of the baseline model was 0.753 (95% CI: 0.694–0.812), which increased to 0.771 (95% CI: 0.712–0.831) after adding Lp(a). DCA showed that the Lp(a)-guided strategy provided higher net benefit than both the “treat-all” and “treat-none” strategies within a threshold probability range of 0–0.35.
Conclusions
Although Lp(a) offers limited incremental value over traditional risk factors and the Gensini score in the low-to-moderate risk range (
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, The Fourth Afffliated Hospital of Harbin Medical University, Harbin 150001, China.
Förderung
- Harbin Medical University
Zitieren
APA
Li, X., Zhang, H., Bai, J., Shi, S., & Sun, C. (2026). Lipoprotein(a) as a Predictor of Major Adverse Cardiovascular Events in Patients with Acute Coronary Syndrome. Journal of Clinical Medicine, 15(15), 6086. https://doi.org/10.3390/jcm15156086
Vancouver
Li X, Zhang H, Bai J, Shi S, Sun C. Lipoprotein(a) as a Predictor of Major Adverse Cardiovascular Events in Patients with Acute Coronary Syndrome. Journal of Clinical Medicine. 2026;15(15):6086. doi:10.3390/jcm15156086
BibTeX
@article{Li2026,
author = {Li, Xinhang and Zhang, Huidi and Bai, Jiaxu and Shi, Shuai and Sun, Chaoyu},
title = {Lipoprotein(a) as a Predictor of Major Adverse Cardiovascular Events in Patients with Acute Coronary Syndrome},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {15},
pages = {6086},
doi = {10.3390/jcm15156086}
}
EUVIMED